Mar 06, 2013, 04.15 PM IST | Source: Tech2.com
Samsung is simply killing it when it comes to global smartphone marketshare and they aim to take the same route for tablets as well. Apple still very much has
Samsung is simply killing it when it comes to the global smartphone market share and they aim to take the same route for tablets as well. Apple still very much has the upper hand when it comes to the tablet market and even though Samsung has had some success in the past with tablets like the Note 10.1, the overall Android tablet segment hasn’t really taken off the way smartphones have. Whether that changes or not this year remains to be seen, but what we know is that Samsung is pulling out all the stops. The newly announced, Samsung Galaxy Note 8.0 or 510 should be hitting store shelves by the end of March and the only real competitor in its sights is the Apple iPad mini. Let’s take a quick look at both these tablets and see how they stack up in a grudge match. Samsung Galaxy Note 510Let’s start with the Note 510. Samsung has had a 7-inch, 7.7-inch and a 10.1-inch tablet in the past which makes the Tab 510 their first 8-inch tablet. Its quite evident that they are after the iPad mini’s market share since this form factor seems to be doing quite well as it offers the best compromise between a smartphone and a full-blown tablet. From whatever time we got to spend with it at the Samsung Forum in Hyderabad, we found the build quality to be quite solid despite it being mostly plastic. The tablet has a decently high resolution, enough to not notice too much pixilation when used from the normal distance.
READ MORE ON Samsung Galaxy Note 510, Samsung Galaxy Note 8.0, Samsung Galaxy Note 510 vs Apple iPad mini, Samsung Galaxy Note 510 launch india, Samsung Galaxy Note 510 price, Samsung Galaxy Note 510 price in india, Samsung Galaxy Note 510 vs apple ipad mini 2, Samsung Galaxy Note 510 vs new ipad mini, Samsung Galaxy Note 510 tablet, samsung, galaxy note 510, note 510, apple, ipad mini, ios, android
ADS BY GOOGLE
video of the day
Gung-ho over pharma; see BPCL rise 30-40% more: Dimensions